blank LMU Munich Faculty for Chemistry and Pharmacy


The Merkel Lab is currently funded by the following grants:

European Research Council
ERC-2014-StG – 637830 October 2015 until December 2021
Biocompatible nanoparticles for T cell targeted siRNA delivery as novel asthma therapy
The goal of this study is to develop an inhalable powder therapy of nanoparticles that deliver siRNA against the Th2 transcription factor GATA-3 specifically into activated T cells ex vivo and in vivo to inhibit the downstream inflammatory cascades.
PI: Olivia Merkel

AbbVie Deutschland GmbH
Nose-to-Brain Delivery
The goal of our joint project is the development of nanoformulations for efficient drug delivery to the brain via intranasal administration.
PI: Olivia Merkel


Bavarian Research Foundation, Daiichi-Sankyo Europe
AZ-1449-20C Nov 2020 until Nov 2021
mRNA Delivery to Dentritic Cells for specific, efficient immunization
The goal of this study is to develop a well tolerated RNA-based vaccine against SARS-CoV-2. Modified and stable mRNA coding for the receptor binding domain of the virus will be encapsulated in a nanocarrier system for optimized activation of lymphocytes and an active immunization.
PIs: Urbanetz, Merkel


Center for NanoScience (CeNS)
Pilot Project Nov 2020-Nov 2021
Development of a Lung-on-a-Chip Model as Screening Device for Assessing Antiviral Pulmonary siRNA Delivery
The goal of the project is to develop a lung-on-a-chip model for screening efficacy of pulmonary siRNA delivery in terms of mucus diffusion and intracellular uptake in an environment mimicking the conditions in the lung with decreased translocation into the circulation.
PIs: Merkel, von Guttenberg (ibidi)

Previous Funding

2014_A299 July 2016 until April 2020
Novel Carrier Systems for Delivery of Biologics across the Blood Brain Barrier
The goal of this study is to develop novel carrier systems that encapsulate nucleic acids, proteins and both for therapeutic delivery across the BBB for the treatment of Alzheimer’s disease.
PI: Fricker, co-PIs: Merkel, Müller

Nanosystems Initiative Munich January 2017 until October 2017
Cellular Delivery Strategies of a Novel Kras Inhibitor
The aim of this study is to formulate a small molecule that has been shown to inhibit Kras in vitro as biodegradable nanoparticles for in vitro and in vivo Kras inhibition.
PIs: Vollmar and Merkel

Nanosystems Initiative Munich January 2017 until October 2017
Multifunctional mesoporous silica nanoparticles for siRNA delivery against TNFα as potential therapy for rheumatoid arthritis
The aim of this study is to develop MSNs that are loaded with siRNA and targeted toward activated macrophages for TNFa downregulation.
PIs: Merkel and Bein

Deutsche Gesellschaft für Muskelkranke
Me7/1 May 2017 until April 2018
Genome editing for DMPK-CTG-repeat expansion via receptor mediated targeted delivery of CRISPR-Cas9 vectors to myoblasts
The aim of this study is to develop CRISPR-Cas9 nanoparticles targeted toward myoblasts for replacement genome editing of repeat units as potential treatment for muscular dystrophy.
PI: Merkel

Fondazione Ricerca Fibrosi Cistica
FFC#23/2017 September 2017 until August 2019
Enabling pulmonary delivery of siRNA in cystic fibrosis lung inflammation: therapeutic potential of hybrid lipid/polymer nanoparticles
The aim of this study is to develop lipid/polymer hybrid nanoparticles for pulmonary delivery of siRNA against NFkB to address lung inflammation in cystic fibrosis.
PIs: Ungaro, Merkel